エルドステインの世界市場

エルドステインの世界市場は2030年までに7,360万米ドルに達する見込み

2024年に5,260万米ドルと推定されるエルドステインの世界市場は、2024～2030年の分析期間にCAGR 5.8%で成長し、2030年には7,360万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである気管支炎は、CAGR 5.1％を記録し、分析期間終了時には2,930万米ドルに達すると予測されます。COPDセグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は1,430万米ドルと推定、中国はCAGR 8.9％で成長予測

米国のエルドステイン市場は、2024年には1,430万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 8.9%で推移し、2030年には予測市場規模1,480万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9％と5.6％と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界のエルドステイン市場- 主要動向と促進要因のまとめ

エルドステインが呼吸器治療で注目される理由とは？

慢性呼吸器疾患の治療に広く使用されている粘液溶解剤であるエルドステインは、慢性閉塞性肺疾患（COPD）、気管支炎、喘息などの疾患の管理に有効であることから、ますます人気が高まっています。粘液の粘度を下げ、痰を出しやすくし、気道クリアランスを改善することで効果を発揮します。大気汚染、喫煙、高齢化により呼吸器疾患の有病率が上昇する中、エルドステインに基づく薬剤の需要は増加傾向にあります。

臨床調査でも、エルドステインの抗炎症作用や抗酸化作用が強調されており、呼吸器疾患に対する併用療法に好んで使用されています。特に慢性肺疾患患者を中心に、病院と在宅ケアの両方で処方が増えています。規制当局の承認とその効能に対する認識の高まりが、市場拡大をさらに後押ししています。

製剤技術革新によるエルドステイン治療の向上は？

製薬会社は、バイオアベイラビリティと患者のアドヒアランスを高める高度なエルドステイン製剤の開発に注力しています。さまざまな患者のニーズに対応するため、発泡性錠剤、放出制御カプセル、液剤が導入されています。

さらに、長期のCOVID関連肺合併症を含む、ウイルス感染後の呼吸器症候群管理におけるエルドステインの可能性を調査しています。エルドステインと他の気管支拡張薬やコルチコステロイドとの併用は、治療成績を最適化するために研究されています。呼吸器ケアの進歩が進むにつれ、エルドステインの肺疾患管理における役割は拡大すると予想されます。

エルドステイン市場の成長を促進する主な要因は？

エルドステイン市場の成長は、呼吸器疾患の有病率の増加、薬剤製剤の進歩、効果的な粘液溶解剤に対する需要の高まりによってもたらされます。高齢者人口の増加と大気汚染レベルの上昇が、COPDや気管支炎の症例増加に寄与し、エルドステインの採用に拍車をかけています。

呼吸器の健康を促進する政府の取り組みや、エルドステインの幅広い治療可能性に関する製薬研究の拡大は、市場の成長をさらに加速させています。新しい製剤や併用療法が登場するにつれ、エルドステインは呼吸器治療プロトコルで重要な役割を果たすことが期待されています。

セグメント

用途（気管支炎、COPD、鼻咽頭炎、その他）;最終用途（製薬会社、CMO、研究機関）

調査対象企業の例

• Alfa Chemistry
• Aurore Life Sciences
• BOC Sciences
• Hwail Pharmaceutical
• Manus Aktteva Biopharma LLP
• Recipharm AB
• Reine Lifescience
• SimSon Pharma Limited
• Taj Pharmaceuticals Ltd.
• United States Biological

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Erdosteine Market to Reach US$73.6 Million by 2030

The global market for Erdosteine estimated at US$52.6 Million in the year 2024, is expected to reach US$73.6 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Bronchitis, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$29.3 Million by the end of the analysis period. Growth in the COPD segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.3 Million While China is Forecast to Grow at 8.9% CAGR

The Erdosteine market in the U.S. is estimated at US$14.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.8 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Erdosteine Market - Key Trends & Drivers Summarized

Why Is Erdosteine Gaining Prominence in Respiratory Treatments?

Erdosteine, a mucolytic agent widely used for treating chronic respiratory diseases, is becoming increasingly popular due to its effectiveness in managing conditions such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. It works by reducing mucus viscosity, facilitating easier expectoration, and improving airway clearance. With the rising prevalence of respiratory disorders due to air pollution, smoking, and aging populations, demand for Erdosteine-based medications is on the rise.

Clinical research has also highlighted Erdosteine’s anti-inflammatory and antioxidant properties, making it a preferred choice in combination therapies for respiratory conditions. The drug is being increasingly prescribed in both hospital and home-care settings, particularly for patients with chronic lung diseases. Regulatory approvals and growing awareness of its benefits are further driving market expansion.

How Are Innovations in Drug Formulation Improving Erdosteine Treatments?

Pharmaceutical companies are focusing on developing advanced Erdosteine formulations that enhance bioavailability and patient adherence. Effervescent tablets, controlled-release capsules, and liquid formulations are being introduced to cater to different patient needs.

Additionally, research is exploring Erdosteine’s potential in post-viral respiratory syndrome management, including long COVID-related lung complications. The combination of Erdosteine with other bronchodilators and corticosteroids is being investigated to optimize treatment outcomes. As advancements in respiratory care continue, Erdosteine’s role in pulmonary disease management is expected to expand.

What Are the Key Factors Driving Growth in the Erdosteine Market?

The growth in the Erdosteine market is driven by increasing respiratory disease prevalence, advancements in drug formulation, and rising demand for effective mucolytic agents. The growing elderly population, coupled with higher air pollution levels, is contributing to increased cases of COPD and bronchitis, fueling Erdosteine adoption.

Government initiatives promoting respiratory health and the expansion of pharmaceutical research into Erdosteine’s broader therapeutic potential are further accelerating market growth. As new formulations and combination therapies emerge, Erdosteine is expected to play a crucial role in respiratory treatment protocols.

SCOPE OF STUDY:

The report analyzes the Erdosteine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Bronchitis, COPD, Nasopharyngitis, Others); End-Use (Pharmaceuticals, CMOs, Research institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Alfa Chemistry
• Aurore Life Sciences
• BOC Sciences
• Hwail Pharmaceutical
• Manus Aktteva Biopharma LLP
• Recipharm AB
• Reine Lifescience
• SimSon Pharma Limited
• Taj Pharmaceuticals Ltd.
• United States Biological

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Erdosteine - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Respiratory Diseases Spurs Demand for Erdosteine-Based Therapies
  • Increasing Geriatric Population Strengthens Business Case for Mucolytic Drug Adoption
  • Growth in Smoking-Related Ailments Expands Addressable Market Opportunity for Erdosteine
  • Adoption of Preventive Healthcare Practices Drives Demand for Long-Term Respiratory Medications
  • Rising Air Pollution Levels Throws the Spotlight on Respiratory Health Solutions
  • Regulatory Support for Mucolytics in Europe Drives Erdosteine Market Penetration
  • Growing Focus on Patient-Centric Drug Delivery Systems Enhances Market Appeal of Erdosteine
  • Expansion of Pulmonary Rehabilitation Programs Accelerates Use of Adjunct Mucolytic Therapies
  • Shift Towards Evidence-Based Prescriptions Sustains Growth in Erdosteine Adoption
  • Increasing Healthcare Spending in Emerging Markets Propels Growth of Erdosteine Consumption
  • Advancements in Formulation Technology Drive Adoption of Sustained-Release Erdosteine Products
  • Rising Demand for Antibiotic-Sparing Therapies Strengthens Market Position of Erdosteine
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Erdosteine Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Erdosteine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Bronchitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Bronchitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Bronchitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for COPD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for COPD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Nasopharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Nasopharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Nasopharyngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for CMOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for CMOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for CMOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Research institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• JAPAN
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: Japan 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• CHINA
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: China 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• EUROPE
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Erdosteine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• FRANCE
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: France 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• GERMANY
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Germany 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Italy 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: UK 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Spain 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Spain 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: Russia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Russia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Erdosteine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Australia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Australia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• INDIA
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: India 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: India 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: South Korea 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: South Korea 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Erdosteine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Latin America 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Latin America 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Argentina 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Argentina 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Brazil 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Brazil 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Mexico 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Mexico 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Erdosteine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Erdosteine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Middle East 15-Year Perspective for Erdosteine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Middle East 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: Iran 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: Iran 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Israel 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Israel 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: UAE 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: UAE 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030
• AFRICA
  • Erdosteine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Erdosteine by Application - Bronchitis, COPD, Nasopharyngitis and Others Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Africa 15-Year Perspective for Erdosteine by Application - Percentage Breakdown of Value Sales for Bronchitis, COPD, Nasopharyngitis and Others for the Years 2015, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Erdosteine by End-Use - Pharmaceuticals, CMOs and Research institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Africa 15-Year Perspective for Erdosteine by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals, CMOs and Research institutes for the Years 2015, 2025 & 2030

IV. COMPETITION